Newer Injectable Treatments for HIV and Current Accessibility in the US and Around the World

Author(s)	Manaswi Chigurupati
Country	United States
Abstract	Human immunodeficiency virus (HIV) remains a major public health challenge worldwide, with 38 million individuals living with the virus. Recent advancements in antiretroviral therapy (ART) have introduced long-acting injectable treatments such as cabotegravir and rilpivirine, which address challenges associated with adherence to daily oral regimens. This manuscript reviews the efficacy and safety of injectable ART, accessibility barriers in the U.S. and globally, and potential strategies to overcome these challenges. By leveraging innovative policies and collaborative initiatives, equitable access to injectable ART can be achieved, improving outcomes for underserved populations. The review highlights the significance of addressing systemic barriers to ensure that the benefits of injectable ART reach all populations, contributing to the global fight against HIV.
Keywords	HIV, Injectable ART, Cabotegravir, Rilpivirine, Global Health Equity, Accessibility, Healthcare Disparities
Published In	Volume 3, Issue 12, December 2022
Published On	2022-12-06
Cite This	Newer Injectable Treatments for HIV and Current Accessibility in the US and Around the World - Manaswi Chigurupati - IJLRP Volume 3, Issue 12, December 2022. DOI 10.5281/zenodo.14905607
DOI	https://doi.org/10.5281/zenodo.14905607
Short DOI	https://doi.org/g85r35

About IJLRP Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijlrp.com

International Journal of Leading Research Publication